Starpharma (ASX:SPL) share price slips after posting loss

The Starpharma (ASX: SPL) share price has dipped today after the company reported a $10 million loss. Here are the details.

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price is in the red today, slipping 0.47% at the time of writing to $2.13.

The biotechnology company develops new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery, VivaGel and Viraleze.

 Stapharma reported its half-year results earlier today. This is what we found out.

Starpharma posts half-year losses

Starpharma reported that its total revenue for the first half of FY21 (1H21) was $638,000, down 89% on the previous corresponding period.

The company also incurred a loss after tax of $10.4 million in 1H21, which was 78% greater than that incurred in 1H20. It attributed the loss to lower revenue generated during the period.

Basic loss per share was $2.69 in 1H21 compared to a loss per share of $1.58 in 1H20.

However, Starpharma's net assets more than doubled during the period and it finished off the half with a value of $69.9 million. In contrast to $31.3 million net assets in 1H20.

The cash balance as of 31 December 2021 was $70.3 million, a significant leap from $35.9 million at the end of 1HY20.

CEO commentary

Starpharma CEO Dr Jackie Fairley said the company "achieved multiple significant milestones in the recent period". These included the rapid development of its Viraleze antiviral nasal spray and signing two new partnerships:

These new partnerships illustrate the broad applicability of the DEP® platform and its use for multiple therapeutic areas.

We also progressed our other partnered DEP® programs and recently announced AstraZeneca's global expansion of its phase 1 trial for DEP® AZD0466 which is designed to expedite the development of this exciting novel drug.

Dr Fairley also advised that additional clinical trial programs were progressing as the company continued to focus on expanding the availability of its products.

Starpharma share price snapshot

The Starpharma share price has gained 89.09% over the past year.

There are currently 406 million shares outstanding. The Starpharma market capitalisation presently stands at $897.3 million.

Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Record Highs

The ASX 200 Index is on its way to another all-time high today. Here's why

These blue chip stocks are driving the index towards a new record today...

Read more »

Group of friends trading stocks on their phones. symbolising the 3 most traded ASX 200 shares today
Share Market News

3 ASX mining stocks topping the most-traded list in October

Chinese stimulus news and company announcements likely contributed to the higher trading activity.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

Two people tired and resting after sports race.
Broker Notes

Fundie rates 2 ASX 200 stocks in short-term pain but with long-term gain potential

Blackwattle Investment Partners sees these 2 ASX 200 stocks as worthy of a buy and hold strategy.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Megaport, Pilbara Minerals, Vysarn, and WiseTech shares are falling today

These shares are ending the week in the red. But why?

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »